Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Infectious & Toxicology
Filter     Order     Display # 
Date Item Title
04 Mar 2008 Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
04 Mar 2008 UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
29 Feb 2008 Phase II Clinical Trial of ALN-RSV01 Demonstrates Statistically Significant Anti-Viral Efficacy with an Approximately 40% Reduction in RSV Infection Rate and 95% Increase in Infection-Free Subjects
27 Feb 2008 Intercell completes Phase I clinical trial for improved seasonal Flu vaccine formulated with IC31(R)
25 Feb 2008 Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School
25 Feb 2008 OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
25 Feb 2008 GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
22 Feb 2008 Astellas Receives Positive Opinion From CHMP for Mycamine(R) for the Treatment of Serious Fungal Infections
20 Feb 2008 GlaxoSmithKline receives favourable recommendation by FDA Advisory Committee for Rotarix(R)
14 Feb 2008 Vaccine formulated with Intercell's adjuvant IC31(R) part of a broader collaboration to fight TB
13 Feb 2008 Cytheris Announces 48-Week Results of Phase I/II Study Showing Administration of Interleukin-7 (IL-7) Significantly Improves CD4 T-Cell Counts in Chronically Infected HIV-1 Patients
12 Feb 2008 Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
12 Feb 2008 Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
11 Feb 2008 SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
07 Feb 2008 Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II
07 Feb 2008 GeoVax Labs, Inc.'s Promising HIV/AIDS Vaccine Trial Data Presented at Retrovirus Conference
07 Feb 2008 Inhibitex HIV Integrase Inhibitor Data Presented at 15th Annual Conference on Retroviruses and Opportunistic Infections
07 Feb 2008 New 48-Week Efficacy and Safety Data Presented for Intelencetm (Etravirine) As Part of HIV Combination Therapy
06 Feb 2008 Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections
06 Feb 2008 IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
06 Feb 2008 OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
06 Feb 2008 Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
06 Feb 2008 Bevirimat Data Presented at 15th Conference on Retroviruses and Opportunistic Infections
05 Feb 2008 4SC and AiCuris begin collaboration for the discovery of anti-infective drug candidates
05 Feb 2008 Manhattan Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Hedrin
04 Feb 2008 MedImmune Submits Biologics License Application to FDA for Motavizumab
28 Jan 2008 Broad-spectrum Oral Antibacterial Agent Gracevit(R) Tablets 50 mg/fine granules 10% Receives Approval for Manufacturing and Marketing
23 Jan 2008 Human Genome Sciences Modifies Dosing In Achieve Trials of Albuferon(R)
23 Jan 2008 Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
23 Jan 2008 Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor
23 Jan 2008 BioCryst Updates Peramivir Clinical Development Plan
22 Jan 2008 Arpida reports progress in pivotal Phase III trial with TLT treatment in onychomycosis
22 Jan 2008 Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
22 Jan 2008 Medicago’s Pandemic Flu Vaccine Provides 100% Protection in Mice at Low Doses
22 Jan 2008 NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA
22 Jan 2008 Protalix Biotherapeutics Extends Research Agreement With Yissum Ltd. Based on Promising Acetylcholinesterase Program Results in Animal Study
18 Jan 2008 FDA Approves New HIV Drug After Priority Review
16 Jan 2008 ICLL receives manufacturer's licence for future commercial manufacturing of its JE vaccine
16 Jan 2008 Intercell and PATH Malaria Vaccine Initiative Announce New Collaboration for Vaccine against Malaria
15 Jan 2008 Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
14 Jan 2008 Inspire Announces Its Termination of Bilastine Licensing Agreement
14 Jan 2008 Schering-Plough Reports Top-Line Results of the IDEAL Study
14 Jan 2008 Three Rivers Pharmaceuticals®, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
09 Jan 2008 New data show Menveo(TM) to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants
07 Jan 2008 Tacere Therapeutics Eenters Collaborationa and License Agreement With Pfizer to Develop and Commercilize RNAi Hepatitis C Drug
07 Jan 2008 InterMune Announces Continuing Progress on ITMN-191 (R7227)
07 Jan 2008 Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
07 Jan 2008 Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
04 Jan 2008 Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
03 Jan 2008 Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 301 - 350 of 1267

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics